EC Number   |
General Information |
Reference |
|---|
    1.4.3.4 | drug target |
active monoamine oxidase inhibitors represent suitable leads for the development of drugs for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression. Monoamine oxidase inhibitors are also of interest for the treatment of prostate cancer, certain types of cardiomyopathies and Alzheimer's disease |
764555 |
| 1.4.3.4 | drug target |
inhibitors of MAO-A and MAO-B isozymes are useful as antidepressants and neuroprotectants |
765139 |
| 1.4.3.4 | malfunction |
abnormal MAO A activity is implicated in several neuropsychiatric disorders, such as depression, autism, and attention deficit hyperactivity disorder, which show sexual dimorphism |
703615 |
| 1.4.3.4 | malfunction |
individual polymorphisms of the promoter of MAO-A gene might partly explain the increased vulnerability of maltreated male children for externalizing behaviour, overview |
706679 |
| 1.4.3.4 | malfunction |
polymorphisms in the gene encoding MAOA are implicated in autism spectrum disorder,overview |
705925 |
| 1.4.3.4 | malfunction |
the first step of the bioactivation of the Parkinsonian-inducing pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, is catalyzed by MAO-B, resulting in the ultimate product, 1-methyl-4-phenylpyridinium, a mitochondrial toxin that causes selective degeneration of nigrostriatal dopaminergic neurons in humans and experimental animals |
705940 |
| 1.4.3.4 | metabolism |
monoamine oxidase (MAO) enzymes catalyze the oxidative deamination of biogenic amines and neurotransmitters and produce ammonia, aldehydes, and hydrogen peroxide which is involved in oxidative processes |
765139 |
| 1.4.3.4 | metabolism |
monoamine oxidase are key role enzymes in the catabolism of amines like dopamine, norepinephrine, epinephrine, serotonin, and 2-phenylethylamine |
711912 |
| 1.4.3.4 | metabolism |
monoamine oxidases catalyse the oxidation of neurotransmitter amines and a wide variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs. While inhibition of MAO activity in the periphery removes protection from biogenic amines and so is undesirable, inhibition in the brain gives vital antidepressant and behavioural advantages that make MAO a major pharmaceutical target for inhibitor design |
765254 |
| 1.4.3.4 | more |
zMAO exhibits no immuno-chemical cross-reactivity with polyclonal anti-sera raised against human MAO-A |
713457 |
